Palo Alto Investors »

Alnylam Pharmaceuticals shares owned by Palo Alto Investors

Quarter-by-quarter ownership of Alnylam Pharmaceuticals (ALNY) shares owned by Palo Alto Investors from 13F filings

Historical chart of Palo Alto Investors investment in Alnylam Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals held by Palo Alto Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals by Palo Alto Investors

Quarter filed Position value Share count Share price at filing
2023-12-31 $30M 154k 191.41

More positions owned by Palo Alto Investors

Insmed Com Par $.01 (INSM)
Amicus Therapeutics (FOLD)
BioMarin Pharmaceutical (BMRN)
Biogen Idec (BIIB)
United Therapeutics Corporation (UTHR)
ACADIA Pharmaceuticals (ACAD)
Prothena Corp SHS (PRTA)
Revance Therapeutics (RVNC)
Staar Surgical Com Par $0.01 (STAA)
Alnylam Pharmaceuticals (ALNY)
eHealth (EHTH)
Sage Therapeutics (SAGE)
Sarepta Therapeutics (SRPT)
Iovance Biotherapeutics (IOVA)
Alkermes SHS (ALKS)

View all positions for Palo Alto Investors

Top funds holding Alnylam Pharmaceuticals

Vanguard Group
Wellington Management Company
Baillie Gifford & Co
Dodge & Cox
T. Rowe Price Associates
Jpmorgan Chase & Co
Norges Bank Investment Management
venBio Select Advisor
Legal & General Group
Bellevue Group
Bank of New York Mellon
Ubs Global Asset Management Americas
Amundi
Gilder, Gagnon, Howe & Co
Alliancebernstein

View all funds holding Alnylam Pharmaceuticals